For patients with platinum-sensitive relapsed ovarian cancer with a partial or complete response to platinum-based chemotherapy, PARP inhibitors niraparib, olaparib, and rucaparib are approved by the FDA for maintenance therapy. These patients were not treated with prior PARP inhibitor therapy in th...

Another unanswered issue in therapy. In the OReO trial, less than 10% of patients met this criteria. However, extrapolating from OReO, the response to reinduction with platinum would suggest that as a “functional” biomarker, there may be some benefit to retreatment in maintenance. Unfort...

This is a good question, without a data-driven answer at the moment. For patients who received PARP inhibitor therapy with upfront treatment/maintenance, who have had a good response to second line chemo for platinum sensitive recurrence, I will discuss the possibility of retreatment with a differen...

I have not, but I would not rule it out. In general, at this time, I would put these patients on UP-NEXT trial if they qualify, and, if not, incorporate bev into their platinum regimen and use bev maintenance. The OReO trial looked at rechallenge with parp in patients with platinum sensitive recurre...

For these patients, I would consider offering retreatment with a PARP inhibitor. The preliminary results from the Phase IIIb OReO/ENGOT Ov-38 trial demonstrated a median PFS of 5.3 months with maintenance olaparib versus 2.8 months with placebo (HR 0.43, 95% CI 0.26-0.71) among 108 BRCAwt patients w...